# A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

> **NCT04233801** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 219 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04233801
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2022-03-03
- **Final completion:** 2022-03-10
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233801, "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04233801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*